Rankings
▼
Calendar
VRCA
Verrica Pharmaceuticals Inc.
$56M
Q4 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
+2823.5% YoY
Gross Profit
-$19M
-934.6% margin
Operating Income
-$23M
-1163.8% margin
Net Income
-$25M
-1238.1% margin
EPS (Diluted)
$-5.31
QoQ Revenue Growth
-31.8%
Cash Flow
Operating Cash Flow
-$15M
Free Cash Flow
-$15M
Stock-Based Comp.
$2M
Balance Sheet
Total Assets
$82M
Total Liabilities
$62M
Stockholders' Equity
$20M
Cash & Equivalents
$70M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$68,000
+2823.5%
Gross Profit
-$19M
-$3M
-514.8%
Operating Income
-$23M
-$6M
-272.5%
Net Income
-$25M
-$6M
-314.9%
Revenue Segments
Product
$2M
85%
Collaboration
$341,000
15%
← FY 2023
All Quarters
Q1 2024 →
VRCA Q4 2023 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena